List of Excipients in API ofatumumab
✉ Email this page to a colleague
Detailed excipient profiles for ofatumumab
Excipient focus: ARGININE
ofatumumab drug variants containing ARGININE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing ARGININE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
ofatumumab drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
ofatumumab drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
ofatumumab drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ACETATE
ofatumumab drug variants containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
ofatumumab drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
ofatumumab drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-0669 |
| Novartis Pharmaceuticals Corporation | ofatumumab | 0078-1007 |
| >Company | >Ingredient | >NDC |
ofatumumab drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch